Is Retatrutide FDA Approved? Status, Trials & Timeline (2026)

Is Retatrutide FDA Approved?

No, retatrutide is not FDA-approved. As of October 2026, retatrutide (LY3437943) remains an investigational drug. Eli Lilly has reported Phase 3 TRIUMPH results (TRIUMPH-4 in December 2025, TRIUMPH-1 in May 2026, TRIUMPH-2 and -3 in July 2026) but has not submitted it for FDA approval yet. Lilly plans to submit a Biologics License Application (BLA) in Q1 2027, after completing its chemistry, manufacturing and controls package. Approval would follow FDA review of that filing. For detailed information on current and future availability worldwide, see our retatrutide availability by country guide.

This means retatrutide is not available at pharmacies, is not covered by insurance, and cannot be legally prescribed in the United States outside of clinical trial protocols and Lilly's narrow expanded access program (NCT07629401). Off-label compounding is not an exception: the FDA states retatrutide cannot be used in compounding under federal law. FDA-approved obesity medications in the GLP-1 class include Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide) and Foundayo (orforglipron). Retatrutide would be the first triple-agonist (GLP-1 + GIP + glucagon) if approved.

Understanding the FDA Approval Process for Retatrutide

New drugs go through a structured series of clinical trials before the FDA considers approval. Retatrutide has passed the early stages and is now in the final stretch. Here's where it stands:

The Three Trial Phases

What Phase 3 Trials Prove

Phase 3 trials are large, randomized, placebo-controlled studies conducted across multiple sites. They're designed to:

• Confirm the weight loss and metabolic benefits seen in Phase 2
• Identify rare side effects that smaller trials might have missed
• Demonstrate consistent results across diverse populations (age, sex, ethnicity, comorbidities)
• Build long-term safety data (cardiovascular outcomes, liver health, kidney function)
• Provide the evidence package the FDA needs to approve the drug

Retatrutide's Phase 2 results were strong enough (up to 24.2% weight loss) that Eli Lilly moved it into a large Phase 3 program. But Phase 3 enrollment takes time, the trials themselves run for 1–2 years, and data analysis and FDA review add more months. That's why approval is still years away even though the early data looks good.

The TRIUMPH Phase 3 Trial Program

Eli Lilly's retatrutide Phase 3 program is called TRIUMPH. It includes multiple trials studying retatrutide in different patient populations and for different indications. These results will determine whether retatrutide gets approved, and for which uses.

TRIUMPH Trial Overview

Trial Locations and Enrollment

TRIUMPH trials have been conducted at hundreds of sites across the United States, Europe, Asia, and other regions, but most retatrutide Phase 3 trials are no longer enrolling. You can search for open studies near you at ClinicalTrials.gov or through Eli Lilly's trial finder tool.

Phase 2 Results That Led to Phase 3

Retatrutide's Phase 2 trial results, published in the New England Journal of Medicine in June 2023, were strong enough that Eli Lilly fast-tracked it into one of the largest Phase 3 obesity programs ever run. Here's what the data showed:

Weight Loss by Dose (48 Weeks)

Why this matters: The FDA-approved semaglutide (Wegovy) produced around 15–17% weight loss in its pivotal trials. Tirzepatide (Zepbound) hit around 20–21%. Retatrutide's 24.2% is the highest weight loss figure recorded for any injectable obesity medication in a controlled trial.

Other Key Findings

• Metabolic improvements: Participants saw reductions in A1C (for those with prediabetes or diabetes), fasting glucose, and triglycerides
• Liver fat reduction: Retatrutide reduced liver fat by up to 50%, which is why Eli Lilly added a NASH-specific trial to the Phase 3 program
• Side effects: Mostly gastrointestinal (nausea, diarrhea, constipation), similar to other GLP-1 drugs but manageable with slow titration
• Discontinuation rate: In Phase 3 TRIUMPH-1 (Jastreboff et al., NEJM 2026; adults with obesity or overweight without diabetes), 4.1%, 6.5% and 11.2% of participants on 4, 9 and 12 mg stopped due to adverse events, vs 4.6% on placebo. For comparison, tirzepatide's SURMOUNT-1 trial reported 4.3% to 7.1% vs 2.6% on placebo (separate trials with different populations and durations)

When Will Retatrutide Be FDA Approved?

Based on Eli Lilly's public statements and the typical FDA review timeline, retatrutide approval is most likely in 2027 or early 2028. Here's the projected timeline:

What Could Change the Timeline

• Priority review: If the FDA grants priority review status (for drugs that show significant improvement over existing treatments), the review time drops to 6 months instead of 10–12. Given retatrutide's superior weight loss data, this is possible.
• Safety signals: If Phase 3 trials reveal unexpected safety issues, the timeline extends or approval gets denied.
• Cardiovascular outcomes data: The FDA might want to see cardiovascular outcomes trial results before approval, which could push the date back.
• Simultaneous diabetes approval: Eli Lilly may seek approval for both obesity and type 2 diabetes at the same time, which could complicate or accelerate the timeline depending on the trial results.

How to Access Retatrutide Now (Before FDA Approval)

There's no standard prescription pathway for retatrutide. Clinical trials are the main lawful route, and Lilly's narrow expanded access program (described below) is the only other one. People also encounter two other sources, which are covered here so you know where they stand:

1. Clinical Trial Enrollment

The best option if you qualify. You get pharmaceutical-grade retatrutide for free, full medical supervision, and you contribute to the research that will determine whether the drug gets approved.

• Pros: Free medication, medical monitoring, compensation for time, high-quality product
• Cons: You might receive placebo, strict eligibility criteria, time commitment (regular visits)
• How to find trials: ClinicalTrials.gov, Lilly Trial Guide

The narrow exception: Lilly's expanded access program. Lilly runs an expanded access program for retatrutide before FDA approval, "for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial" (Reuters via KSL). Patients must be 18 or older with a BMI of 35 or more despite tolerating the highest available dose of weight-management therapy, have two or more serious or life-threatening obesity-related complications, be unable to join an ongoing retatrutide (or comparable) trial, and have discussed all standard treatment options, including bariatric surgery, with their doctor (Lilly Medical; ClinicalTrials.gov NCT07629401). The treating physician applies to the FDA as the sponsor of a patient-specific investigational new drug (IND) application and must obtain institutional review board (IRB) approval. Lilly provides the drug at no cost, and direct-to-patient shipping is not available. It is not something a patient can buy.

2. Compounding Pharmacies (Not a Lawful Route)

Some telehealth platforms have marketed compounded retatrutide, but it is not lawful. The FDA states: "Retatrutide and cagrilintide cannot be used in compounding under federal law." Compounding pharmacies (503A or 503B) cannot lawfully supply it, and a prescription does not change that.

• Enforcement: The FDA has warned telehealth companies for marketing retatrutide, API distributors for selling it to compounders, and outsourcing facilities for repackaging it
• Price: There is no lawful compounded price
• Details: See our compounded retatrutide explainer and retatrutide cost guide

3. Research Peptides (Grey Market)

Most retatrutide in circulation comes from research peptide vendors who sell it as "not for human consumption." This is not a lawful route: the FDA has warned companies for illegally selling retatrutide falsely labeled "for research purposes" or "not for human consumption." The peptide is synthesized in labs (mostly in China), vial-filled by domestic or international vendors, and sold without a prescription.

• Pros: Much cheaper than projected list prices (cost scales with dose), no prescription needed, widely available
• Cons: No quality control, contamination risk, no medical oversight, not lawful (FDA warnings), no recourse if something goes wrong
• Risk mitigation: Third-party testing (Janoshik or similar labs), vet vendors through Reddit/peptide forums, start with small orders

Enrolling in a trial (if you qualify), having a physician request Lilly's expanded access program (if you meet its strict criteria), or waiting for FDA approval are the only lawful paths. Compounded retatrutide is not lawful, and the grey-market route carries risks that go beyond what this article can cover. You're self-experimenting with an unapproved drug. Some people are comfortable with that tradeoff. Many aren't.

Retatrutide vs FDA-Approved Alternatives

While you wait for retatrutide approval, two FDA-approved alternatives exist: semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). Here's how they compare:

For a detailed head-to-head comparison, see our retatrutide vs tirzepatide guide.

Why Choose an Approved Drug Over Retatrutide?

• Availability: You can get a prescription today, pick it up at a pharmacy, and have insurance cover part or all of it (if eligible)
• Safety data: Millions of people have used semaglutide and tirzepatide. Long-term safety is better understood.
• Medical support: Your doctor is familiar with these medications and can manage side effects and dose adjustments
• Quality assurance: FDA-approved drugs are manufactured under strict standards. No guesswork about what's in the vial.

Retatrutide's edge is an extra 3–4% weight loss in trials. Whether that's worth the wait, the cost, and the uncertainty of using an unapproved drug depends on your situation.

What FDA Approval Will Mean for Retatrutide

Assuming retatrutide gets FDA approval (and based on Phase 2 data, that's very likely), several things change:

1. Commercial Availability

Retatrutide will be manufactured at scale, distributed to pharmacies, and available with a standard prescription. Eli Lilly will likely give it a brand name (similar to how tirzepatide became "Mounjaro" and "Zepbound" for different indications).

2. Insurance Coverage (Maybe)

If approved for type 2 diabetes, most commercial insurance plans will cover it (with prior authorization). If approved for obesity, coverage will be inconsistent. Many insurers still exclude weight management drugs, though this is slowly changing. Medicare Part D does not currently cover obesity medications, though Congress has debated changing that.

3. Manufacturer Savings Programs

Eli Lilly offered a savings card for Mounjaro that brought out-of-pocket costs down to $25/month for commercially insured patients. A similar program for retatrutide is likely, at least during the initial launch period to build market share.

4. Standardized Dosing and Safety Information

FDA approval means the medication comes with a package insert, prescribing information, and post-market safety monitoring. Doctors get clear guidance on who should and shouldn't use it, and patients get a real understanding of the risks and benefits.

5. End of the Grey Market?

Probably not. Tirzepatide got approved and the research peptide market shrank, but it didn't disappear. Plenty of people still use grey-market tirzepatide because $150/month beats $1,000/month. Retatrutide will follow the same pattern. FDA approval gives people a legal, safe option, but it won't kill the underground market.